Source comparison
Tesamorelin + Ipamorelin Blend: Side Effect Comparison
Injection-Site Reactions 40–60% (erythema, induration) 15–25% (tolerance develops) Localized inflammatory response to peptide depot Complete within 48–72 hours Expected and transient. Rotate sites to minimize Cortisol Axis Suppression Rare (<5%) 30–40% Chronic
This comparison does not assign a generated winner or score.
- Injection-Site Reactions
- 40–60% (erythema, induration)
- 15–25% (tolerance develops)
- Localized inflammatory response to peptide depot
- Complete within 48–72 hours
- Expected and transient. Rotate sites to minimize
- Cortisol Axis Suppression
- Rare (<5%)
- 30–40%
- Chronic GH elevation suppresses endogenous GHRH cycling and ACTH response
- 8–12 weeks post-cessation in 90%+
- Most clinically significant long-term risk. Requires monitoring
- Insulin Resistance
- 35–45% (transient fasting glucose elevation)
- 15–20% (persistent glucose intolerance)
- GH-induced hepatic gluconeogenesis and reduced insulin receptor sensitivity
- Resolves in 8–16 weeks in most cases
- Pre-existing metabolic dysfunction amplifies risk
- Lipid Profile Changes
- Neutral or favorable (reduced triglycerides)
- 20–25% (elevated LDL-C, reduced HDL-C)
- Increased hepatic VLDL production and altered lipoprotein processing
- Reverses within 12–16 weeks
- Dose-dependent. Monitor lipid panel at week 12 and 24
- Peripheral Edema
- 15–20%
- 8–12%
- GH-induced sodium retention and increased capillary permeability
- Resolves within 5–7 days of cessation
- Mild and self-limiting. Reduce dose if persistent
- Arthralgia and Joint Stiffness
- 10–15%
- 5–8%
- GH-mediated cartilage and connective tissue proliferation
- Gradual resolution over 4–8 weeks
- More common in patients over 45 or with baseline osteoarthritis